Spots Global Cancer Trial Database for refractory mantle cell lymphoma

Every month we try and update this database with for refractory mantle cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	NCT04007029	CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	NCT00723099	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg...	Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ...	- 69 Years	Fred Hutchinson Cancer Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	NCT04047797	Recurrent Mantl... Refractory Mant...	Ixazomib Ixazomib Citrat... Rituximab	18 Years -	M.D. Anderson Cancer Center
Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma	NCT03219047	Recurrent Mantl... Refractory Mant...	Best Practice Ibrutinib Patient Derived... Personalized Me...	18 Years -	M.D. Anderson Cancer Center
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	NCT01381692	Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal...	Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus	18 Years -	National Cancer Institute (NCI)
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma	NCT01695941	Recurrent B-Cel... Recurrent Mantl... Refractory B-Ce... Refractory Mant...	Alisertib Bortezomib Laboratory Biom... Rituximab	18 Years -	National Cancer Institute (NCI)
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT04659044	Recurrent B-Cel... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory B-Ce... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Mant... Refractory Marg... Refractory Smal...	Polatuzumab Ved... Rituximab Rituximab and H... Venetoclax	18 Years -	Academic and Community Cancer Research United
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	NCT04205409	Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Non-H... Recurrent Plasm... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Marg... Refractory Non-... Refractory Plas... Recurrent Mantl... Refractory Mant...	Nivolumab	18 Years -	University of Washington
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy	NCT04703686	Diffuse Large B... Refractory Indo... Refractory Tran... Refractory Prim... Refractory Mant...	Obinutuzumab RO7082859	18 Years -	The Lymphoma Academic Research Organisation
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)	NCT03206970	Refractory Mant... Relapsed Mantle...	Zanubrutinib	18 Years - 75 Years	BeiGene
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT05910801	Recurrent Mantl... Refractory Mant...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Lenalidomide Lumbar Puncture Magnetic Resona... Positron Emissi... Tafasitamab Venetoclax	18 Years -	Academic and Community Cancer Research United
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	NCT02869633	Blastoid Varian... Recurrent Chron... Recurrent Folli... Recurrent Hodgk... Recurrent Mantl... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Mant...	Ibrutinib Laboratory Biom...	18 Years -	Vanderbilt-Ingram Cancer Center
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	NCT03946878	Blastoid Varian... CCND1 Protein O... CD20 Positive CD5 Positive FCER2 Negative Pleomorphic Var... Recurrent Mantl... Refractory Mant... t(11;14)(q13;q3...	Acalabrutinib Venetoclax	18 Years -	M.D. Anderson Cancer Center
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma	NCT01880567	CCND1 Positive CCND2 Positive CCND3 Positive CD20 Positive Mantle Cell Lym... Recurrent Mantl... Refractory Mant...	Ibrutinib Laboratory Biom... Rituximab	18 Years -	M.D. Anderson Cancer Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial	NCT04872413	Recurrent Mantl... Refractory Mant...	Biospecimen Col... Follow-Up	18 Years -	M.D. Anderson Cancer Center
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)	NCT03206970	Refractory Mant... Relapsed Mantle...	Zanubrutinib	18 Years - 75 Years	BeiGene
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy	NCT01646021	Mantle Cell Lym...	Ibrutinib Temsirolimus	18 Years -	Janssen Research & Development, LLC
Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial	NCT04872413	Recurrent Mantl... Refractory Mant...	Biospecimen Col... Follow-Up	18 Years -	M.D. Anderson Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma	NCT04990778	Recurrent Mantl... Refractory Mant...	Eprenetapopt Venetoclax	18 Years -	M.D. Anderson Cancer Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma	NCT02568553	Recurrent Burki... Recurrent Diffu... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Gray-... Recurrent Mantl... Recurrent Margi... Recurrent Media... Recurrent Non-H... Recurrent Small... Refractory Burk... Refractory Diff... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Gray... Refractory Mant... Refractory Marg... Refractory Medi... Refractory Non-... Refractory Smal...	Blinatumomab Lenalidomide	18 Years -	National Cancer Institute (NCI)
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma	NCT03440567	Recurrent Diffu... Recurrent Mantl... Refractory Diff... Refractory Mant... Transformed Fol...	Autologous Hema... Avelumab Carboplatin Etoposide Phosp... Ibrutinib Ifosfamide Laboratory Biom... Rituximab Utomilumab	18 Years -	City of Hope Medical Center
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma	NCT03440567	Recurrent Diffu... Recurrent Mantl... Refractory Diff... Refractory Mant... Transformed Fol...	Autologous Hema... Avelumab Carboplatin Etoposide Phosp... Ibrutinib Ifosfamide Laboratory Biom... Rituximab Utomilumab	18 Years -	City of Hope Medical Center
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	NCT01955499	Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Ibrutinib Lenalidomide Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes	NCT03061188	Advanced Solid ... Aggressive Non-... Recurrent Solid... Refractory Mant... T-Cell Non-Hodg... Unresectable So...	Laboratory Biom... Nivolumab Pharmacological... Veliparib	18 Years -	Northwestern University
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT04939272	Recurrent Mantl... Refractory Mant...	Copanlisib Hydr... Venetoclax	18 Years -	City of Hope Medical Center
CD19-Specific T Cells Post AlloSCT	NCT03579888	B Acute Lymphob... Recurrent B Acu... Recurrent Chron... Recurrent Diffu... Recurrent Mantl... Recurrent Non-H... Recurrent Ph-Li... Recurrent Prima... Recurrent Small... Refractory B Ac... Refractory Chro... Refractory Diff... Refractory Mant... Refractory Non-... Refractory Ph-L... Refractory Prim... Refractory Smal...	Autologous CD19... Cyclophosphamid... Fludarabine	18 Years - 70 Years	M.D. Anderson Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	NCT01719250	Recurrent Adult... Recurrent Grade... Recurrent Mantl... Refractory Mant... Transformed Rec...	Buparlisib Laboratory Biom... Questionnaire A...	18 Years -	Mayo Clinic
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)	NCT00875667	Mantle Cell Lym... Lymphoma, Mantl...	Lenalidomide Investigators c...	18 Years -	Celgene
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	NCT01897012	MYC Positive Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Hodgk... Recurrent Mantl... Recurrent Matur... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory High... Refractory Hodg... Refractory Mant... Refractory Matu...	Alisertib Laboratory Biom... Romidepsin	18 Years -	National Cancer Institute (NCI)
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	NCT04007029	CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	NCT01381692	Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal...	Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus	18 Years -	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies	NCT01921387	Recurrent B-Cel... Recurrent Hodgk... Recurrent Mantl... Recurrent T-Cel... Refractory B-Ce... Refractory Hodg... Refractory Mant... Refractory T-Ce...	Autologous Hema... Carmustine Cytarabine Etoposide Laboratory Biom... Melphalan Peripheral Bloo... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies	NCT06343376	Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Mantl... Recurrent Trans... Recurrent Trans... Refractory Chro... Refractory Diff... Refractory Foll... Refractory High... Refractory Mant... Refractory Tran... Refractory Tran...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Echocardiograph... EGFRt/19-28z/IL... Fludarabine Pho... Leukapheresis Multigated Acqu... Positron Emissi...	18 Years -	Roswell Park Cancer Institute
Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma	NCT06300528	Recurrent Extra... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Refractory Extr... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Pemigatinib Positron Emissi...	18 Years -	Ohio State University Comprehensive Cancer Center
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy	NCT04703686	Diffuse Large B... Refractory Indo... Refractory Tran... Refractory Prim... Refractory Mant...	Obinutuzumab RO7082859	18 Years -	The Lymphoma Academic Research Organisation
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma	NCT03147885	Diffuse Large B... Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Indol... Recurrent Mantl... Recurrent Margi... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Mant... Stage III Non-H... Stage IV Non-Ho... Transformed Rec...	Selinexor	18 Years -	Barbara Ann Karmanos Cancer Institute
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	NCT04054167	Recurrent Mantl... Refractory Mant...	Low Dose Radiat...	18 Years -	M.D. Anderson Cancer Center
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma	NCT05025800	Aggressive B-Ce... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Composite Lymph... Indolent B-Cell... Refractory Aggr... Refractory Foll... Refractory Grad... Refractory High... Refractory Mant... Refractory Marg... Refractory Prim... Refractory Tran... Refractory Tran... Richter Syndrom...	CD47 Antagonist... Lenalidomide Rituximab	18 Years -	M.D. Anderson Cancer Center
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	NCT02950220	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Mediastinal Lym... Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Walde... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant...	Ibrutinib Laboratory Biom... Pembrolizumab	18 Years -	Ohio State University Comprehensive Cancer Center
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	NCT02489123	Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Recurrent Mantl... Refractory Mant...	Enzalutamide Laboratory Biom...	18 Years -	University of Washington
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT04659044	Recurrent B-Cel... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory B-Ce... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Mant... Refractory Marg... Refractory Smal...	Polatuzumab Ved... Rituximab Rituximab and H... Venetoclax	18 Years -	Academic and Community Cancer Research United
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma	NCT01880567	CCND1 Positive CCND2 Positive CCND3 Positive CD20 Positive Mantle Cell Lym... Recurrent Mantl... Refractory Mant...	Ibrutinib Laboratory Biom... Rituximab	18 Years -	M.D. Anderson Cancer Center
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT04939272	Recurrent Mantl... Refractory Mant...	Copanlisib Hydr... Venetoclax	18 Years -	City of Hope Medical Center
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT05910801	Recurrent Mantl... Refractory Mant...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Lenalidomide Lumbar Puncture Magnetic Resona... Positron Emissi... Tafasitamab Venetoclax	18 Years -	Academic and Community Cancer Research United
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)	NCT00875667	Mantle Cell Lym... Lymphoma, Mantl...	Lenalidomide Investigators c...	18 Years -	Celgene
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	NCT04578600	Indolent B-Cell... Recurrent B-Cel... Recurrent Chron... Recurrent Mucos... Recurrent Folli... Recurrent Hairy... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Chro... Refractory Muco... Refractory Foll... Refractory Hair... Refractory Lymp... Refractory Mant... Refractory Marg... Recurrent Small... Refractory Smal...	Lenalidomide Obinutuzumab Oral Azacitidin...	18 Years -	University of California, Davis
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma	NCT02736617	Recurrent Mantl... Refractory Mant...	Ibrutinib Obinutuzumab	18 Years -	OHSU Knight Cancer Institute
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT05910801	Recurrent Mantl... Refractory Mant...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Lenalidomide Lumbar Puncture Magnetic Resona... Positron Emissi... Tafasitamab Venetoclax	18 Years -	Academic and Community Cancer Research United
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	NCT04007029	CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL	NCT02572453	Recurrent Anapl... Recurrent Diffu... Recurrent Mantl... Recurrent Trans... Refractory Anap... Refractory Diff... Refractory Mant... Refractory Tran...	Onalespib	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: